Naglaa Bazan

Dr. Naglaa Bazan

Cairo University
+1
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2013 in Irish Journal of Medical Science (1971 -)
Verified
Journal Article
Closed access
PDF file
Naglaa BazanNaglaa Bazan
Naglaa Bazan
NSNirmeen A. Sabry
Nirmeen A. Sabry
ARA. Rizk
A. Rizk
SMS. Mokhtar
S. Mokhtar
OBOsama Badary
Osama Badary

14 January 2021 in Irish Journal of Medical Science (1971 -)
Verified
Journal Article
Closed access
PDF file
WAWalid A. Ali
Walid A. Ali
Naglaa BazanNaglaa Bazan
Naglaa Bazan
AEAhmed A. Elberry
Ahmed A. Elberry
RHRaghda R. S. Hussein
Raghda R. S. Hussein

3 January 2022 in Irish Journal of Medical Science (1971 -)
Verified
Journal Article
Closed access
PDF file
DADina Hussein El Adly
Dina Hussein El Adly
Naglaa BazanNaglaa Bazan
Naglaa Bazan
RBRadwa Maher El Borolossy
Radwa Maher El Borolossy
IAIslam Fawzy Anan
Islam Fawzy Anan
MFMohamed Amin Fakher
Mohamed Amin Fakher
LWLamia Mohamed El Wakeel
Lamia Mohamed El Wakeel

27 July 2012 in International Journal of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
Naglaa BazanNaglaa Bazan
Naglaa Bazan
NSNirmeen A. Sabry
Nirmeen A. Sabry
ARAmal Rizk
Amal Rizk
SMSherif Mokhtar
Sherif Mokhtar
OBOsama Badary
Osama Badary

30 August 2018 in International Journal of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
NKNoha Kamal
Noha Kamal
NKNoha Kamal
Noha Kamal
Naglaa BazanNaglaa Bazan
Naglaa Bazan
MHMostafa El Haddad
Mostafa El Haddad

27 June 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CNChristina Medhat Naiim
Christina Medhat Naiim
MEM. M. Elmazar
M. M. Elmazar
NSNagwa ALi Sabri
Nagwa ALi Sabri
Naglaa BazanNaglaa Bazan
Naglaa Bazan
Extended infusion of piperacillin/tazobactam over 4 h has been proposed as an alternate mode of administration to the 30-min intermittent infusion to optimize treatment effects in patients with gram-negative bacterial infections. The study aimed to evaluate the extended infusion regimen of piperacillin/tazobactam in standings of efficacy, safety, and cost to the intermittent one in the treatment of gram-negative bacterial infections. A prospective randomized comparative study was performed on 53 patients, 27 in the intermittent infusion group and 26 in the extended infusion group. The primary outcome was the mean number of days to clinical success and the percentage of patients who were clinically cured after treatment. The secondary outcomes included mortality, readmission within 30-days, and cost-effectiveness analysis based on the mean number of days to clinical success. The clinical success rate was comparable in the two groups. Days on extended infusion were significantly lower than intermittent infusion (5.7 vs 8.9 days, respectively, p = 0.0001) as well as days to clinical success (4.6 vs 8.5 days, respectively, p = 0.026). The extended infusion was superior to the intermittent infusion regarding cost-effectiveness ratio ($1835.41 and $1914.09/expected success, respectively). The more cost-effective regimen was the extended infusion. Both regimens had comparable clinical and microbiological outcomes.